Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Levothyroxine Generic Approvals Upheld In First Court Challenge

Executive Summary

FDA's approval of Sec. 505(b)(2) applications for Alara's Levo-T and Jerome Stevens' Unithroid claiming bioequivalence to King's Levoxyl appears to be appropriate, a D.C. federal court judge ruled

You may also be interested in...



Is FDA Less Confident In ANDAs? Stay On Efudex Generic May Set Precedent

FDA's decision to review its approval of a generic for Valeant's topical Efudex (fluorouracil) Cream 5% may create a precedent for future approvals of ANDAs for complex small molecule drugs and could set the stage for higher hurdles for eventual approvals of biogenerics

Is FDA Less Confident In ANDAs? Stay On Efudex Generic May Set Precedent

FDA's decision to review its approval of a generic for Valeant's topical Efudex (fluorouracil) Cream 5% may create a precedent for future approvals of ANDAs for complex small molecule drugs and could set the stage for higher hurdles for eventual approvals of biogenerics

FDA Approves Generic Of GSK Flonase But Launch Halted By Restraining Order

FDA's approval of generic Flonase has prompted a lawsuit by GlaxoSmithKline representing another challenge by brand manufacturers to the legitimacy of FDA-approved generic drugs

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS044316

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel